Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company focused on developing novel serotonergic agonists (NSAs), has announced significant advancements in its lead product candidate HLP003. The company has completed enrollment in APPROACH, its Phase 3 pivotal study evaluating HLP003 in major depressive disorder (MDD), with topline data expected in the fourth quarter of 2026. Additionally, enrollment is underway in EMBRACE, the second pivotal study in the Phase 3 PARADIGM program, and participants continue to roll over into the EXTEND long-term extension study. These milestones mark crucial steps toward potentially bringing a new treatment option to patients with MDD, a condition affecting millions worldwide.
Beyond HLP003, Helus Pharma is also advancing HLP004 for generalized anxiety disorder (GAD). Following Phase 2 results that demonstrated a statistically significant and clinically meaningful improvement from baseline, the company is progressing toward the next study design, expected to be completed by the end of the third quarter. This progress underscores the company's commitment to addressing unmet needs in mental health, where current therapies often have limitations in efficacy and durability.
The company reported cash and cash equivalents of $166.4 million as of June 30, 2026. For the quarter ended June 30, 2026, Helus Pharma reported a net loss of $47.8 million, compared with $24.6 million in the same period last year. Cash-based operating expenses increased to $37.5 million from $23.9 million a year earlier, driven by the continued advancement of the APPROACH, EMBRACE, and EXTEND Phase 3 trials. The increased investment reflects the company's focus on executing its clinical development programs efficiently.
In addition to its clinical progress, Helus Pharma continues to expand its pipeline. The company is advancing HLP005 toward candidate selection, with a viable development candidate anticipated in the second half of 2027. This early-stage program highlights the company's long-term strategy to build a portfolio of novel NSA candidates targeting various mental health conditions.
The potential impact of these developments is substantial. If HLP003 successfully meets its endpoints in the Phase 3 program, it could offer a new adjunctive treatment option for patients with MDD who have inadequate response to standard antidepressants. Given that MDD is a leading cause of disability worldwide, a new therapy that provides durable improvements could significantly alter treatment paradigms. Similarly, HLP004's advancement in GAD addresses another large patient population with high unmet need.
Helus Pharma, the commercial operating name of Cybin Inc., is dedicated to developing proprietary NSAs—synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. The company's lead candidate, HLP003, has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, underscoring its potential to address a serious condition. The company operates in Canada, the United States, the United Kingdom, and Ireland, and is committed to helping minds heal through innovative science.
For investors and stakeholders, the completion of enrollment in the APPROACH trial and the anticipated topline data in Q4 2026 represent key catalysts. The company's cash position of $166.4 million is expected to fund operations into 2027, providing a runway to achieve these milestones. However, the increased net loss and operating expenses reflect the cost of advancing late-stage clinical trials, which is typical for clinical-stage biopharmaceutical companies.
As Helus Pharma progresses its Phase 3 program and expands its pipeline, the coming months will be critical. The outcomes of the APPROACH and EMBRACE trials will not only determine the future of HLP003 but also validate the company's NSA platform. With a focus on neuroplasticity, these investigational therapies hold promise for transforming mental health care. The company continues to provide updates through its website at www.helus.com and its newsroom at https://ibn.fm/HELP.
